ASCO in Action

ASCO in Action provides the latest news and analysis related to critical policy issues affecting the cancer community, updates on the Association for Clinical Oncology’s ongoing advocacy efforts, and opportunities for members and others in the cancer care community to take action.

To sign up for advocacy alerts, log in to ASCO.org with your member or guest account, and visit the subscription center available under your account profile.

Tune in to the ASCO in Action podcast series for analysis and commentary on cancer policy and practice issues. The podcast is available through iTunes or Google Play.

Showing results for Advocacy

October 13, 2020

The Association for Clinical Oncology recently submitted comments about improving racial health equity, noting that factors including race and ethnicity, age, socioeconomic status, geographic location, and insurance access are known to impact cancer care outcomes.

October 13, 2020

letter from 160 Members of Congress to Department of Health and Human Services (HHS) Secretary Alex Azar and Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma made recommendations regarding the coming update to Evaluation and Management (E&M) services Current Procedural Terminology (CPT ®) codes (99202-99215) in 2021.

October 13, 2020

The Association for Clinical Oncology (ASCO) joined more than 110 organizations representing patients, medical researchers, providers, cancer survivors and their families in signing an endorsement letter for S. 4742, the CLINICAL TREATMENT Act.

October 13, 2020

The Association for Clinical Oncology (ASCO) responded to the Centers for Medicare & Medicaid Services (CMS) Request for Information (RFI) on electronic prescribing of controlled substances (EPCS). ASCO supports safe and unburdened access to opioids for people with cancer and asserts that EPCS provides benefits that can improve the quality of cancer care.

October 1, 2020

The Continuing Resolution provides flat funding for the National Institutes of Health (NIH), the National Cancer Institute (NCI), and the Food and Drug Administration (FDA) through December 11, 2020, and does not include any emergency or additional funding for the NIH to mitigate disruptions to trials/research due to COVID-19.

September 30, 2020

ASCO applauds Senators Richard Burr (R-NC) and Ben Cardin (D-MD) for introducing bipartisan legislation to expand access to clinical trials and improve the quality of cancer research. The CLINICAL TREATMENT Act (S. 4742) would require Medicaid to guarantee coverage of the routine care costs of clinical trial participation for Medicaid enrollees with a life-threatening condition.

September 29, 2020

The Association for Clinical Oncology (ASCO) submitted comments to the Food and Drug Administration (FDA) in response to its Proposed Rule – Annual Summary Reporting Requirements Under the Right to Try Act, which proposes a statutory requirement where sponsors and manufacturers must provide an annual summary of any investigational drugs supplied for use to an eligible patient.

September 22, 2020

The Association for Clinical Oncology (ASCO) held its first-ever virtual Advocacy Summit and online Week of Action September 9 – 18, 2020. The largest Advocacy Summit to date, 170  ASCO volunteer leaders and oncology care providers participated in 200 virtual meetings with Members of Congress and their staff to advocate for policies that would improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research. Participants represented 44 different states, as well as Puerto Rico and the District of Columbia.

September 16, 2020

The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Carolyn Hendricks, MD, FASCO, for her exceptional contributions and commitment to the Association’s advocacy efforts.

September 9, 2020

The Association for Clinical Oncology (ASCO) today presented Representative Rosa DeLauro (CT-3) with the annual Congressional Champion for Cancer Care Award in recognition of her exceptional commitment to bipartisan support for cancer research and treatment. The award honors a Member of Congress who is a leading champion for patients and survivors of cancer, their families, and their cancer care teams.  

September 4, 2020

The Association for Clinical Oncology (ASCO) today released a statement regarding concerns that the U.S. Department of Health and Human Services (HHS) rescission of all guidance and informal issuances related to the Food and Drug Administration’s (FDA) current oversight of the premarket review and approval process for laboratory developed tests (LDTs) puts the safety of cancer treatments at risk.

August 31, 2020

On September 16, the Association for Clinical Oncology (ASCO) will be hosting its first ever completely virtual Advocacy Summit. Oncology care providers from across the United States will meet with Members of Congress and their staff by phone or video to advocate for policies that will improve access to high-quality, equitable care for people with cancer and ensure robust funding for cancer research.

August 26, 2020

The Association for Clinical Oncology (ASCO) recently submitted comments to the Centers for Medicare & Medicaid Services (CMS) on the Medicare and Medicaid Programs; CY 2021 Home Health Prospective Payment System Rate Update; Home Health Quality Reporting Requirements; and Home Infusion Therapy Services Requirements (CMS-1730-P) proposed rule.

August 26, 2020

The Association for Clinical Oncology (ASCO) recently submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) in response to its request for comments on improving patient identification and matching in the nation’s health information technology infrastructure.

August 18, 2020

The Association for Clinical Oncology (ASCO) today released a statement applauding the implementation of the Research to Accelerate Cures and Equity (RACE) for Children Act. As of today, applications to the Food and Drug Administration for marketing approval of new drugs and biological products—including orphan drugs that have relevance to pediatric cancer—must include an assessment of pediatric use. 

Pages